0000899243-20-034282.txt : 20201217
0000899243-20-034282.hdr.sgml : 20201217
20201217160511
ACCESSION NUMBER: 0000899243-20-034282
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201215
FILED AS OF DATE: 20201217
DATE AS OF CHANGE: 20201217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS
CENTRAL INDEX KEY: 0001779990
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38959
FILM NUMBER: 201396147
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BridgeBio Pharma, Inc.
CENTRAL INDEX KEY: 0001743881
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
BUSINESS PHONE: (650) 391-9740
MAIL ADDRESS:
STREET 1: 421 KIPLING STREET
CITY: PALO ALTO
STATE: CA
ZIP: 94301
FORMER COMPANY:
FORMER CONFORMED NAME: BridgeBio Pharma LLC
DATE OF NAME CHANGE: 20180618
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-15
0
0001743881
BridgeBio Pharma, Inc.
BBIO
0001779990
HENDERSON MICHAEL THOMAS
C/O BRIDGEBIO PHARMA, INC.
421 KIPLING STREET
PALO ALTO
CA
94301
0
1
0
0
Chief Business Officer
Stock Option (Right to Buy)
3.07
2020-12-15
4
A
0
4456
0.00
A
2030-04-01
Common Stock
4456
4456
D
Stock Option (Right to Buy)
3.07
2020-12-15
4
A
0
3137
0.00
A
2030-07-20
Common Stock
3137
3137
D
Stock Option (Right to Buy)
42.80
2020-12-15
4
A
0
2199
0.00
A
2030-09-29
Common Stock
2199
2199
D
The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio.
1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date.
/s/ Tara Condon, Attorney-in-Fact
2020-12-17